Hat die jemand
Seite 1 von 14 Neuester Beitrag: 29.08.16 15:07 | ||||
| Eröffnet am: | 22.03.14 23:25 | von: Master Mint | Anzahl Beiträge: | 328 |
| Neuester Beitrag: | 29.08.16 15:07 | von: Cobra7 | Leser gesamt: | 71.330 |
| Forum: | Hot-Stocks | Leser heute: | 30 | |
| Bewertet mit: |  | |||
| Seite: < | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... 14 > | ||||
Hab schon Diverse Informationen mir reingezogen und denke mal das man hier gut belohnt wird.
Leider gab es bisher nur einen Analysten der hier auf 3 $ stuft aber die Zeit wird es bringen denke ich.
Auch ist Hemis noch nicht soweit wie andere davon geflogen also bleibe ich gespannt.
Ist aber auch schön, das ich hier nicht alleine rumhänge.
Schöne Woche wünscht Master Mint
Es wirkt ja wohl gegen Viren (Grippe Panthemie Angst -> Zulassungserwägung).
Wäre damit z.B. HIV dauerhaft bekämpfbar?
Nur das ist ja nicht gewollt, infizierte sollen möglicht lange leben, aber nicht geheilt werden, bringt mehr Geld.
Was ist nun mit der aktuellen Ebola Epidemie?
Kann Ampligen da helfen?
Erster Ebola-Fall in den USA
NTV
Optionen
| Boardmail an "Braindead0195" |
Wertpapier: Hemispherx Biopharma |
Und ich Depp hab vor ein paar Wochen 3/4 verkauft.
Da beiß ich mir doch glatt wieder in den Allerwertesten :)
Verdammt
und nun hoffen, dass sie womöglich was zu ebola ankündigen.
dann wirds recht nett. ist es aber so schon.
master, ich wollte erst auch werfen. habe dann aber gekauft.
zum glück....
https://de.finance.yahoo.com/q?s=HEB&ql=0
Jedenfalls haben wir heute ein schönes Volumen und das sollte nachhaltig ausreichen um bessere Kurse zu sehen.
Wenn nicht, na dann muß ich weiter warten :)
This listed on the NYSE-AMEX how to regulate what is happening in the market, I guess reflecting what until now had in its fundamental side, back room or kitchen, as I call it, announced on September 29, a set in various research collaborations with various partners, aimed at developing therapeutic solutions for any kind against Ebola, which could cope with the emergence of drug resistance that could be used because of potential mutations of that virus.
The rapid variation in the genomic sequence of Ebola virus (EVD) in Ebola virus (EBOV) observed, is ahead of many pharmaceutical companies the suggestion of working on drugs that are prepared to combat the risk of mutation that may arise and that would theoretically failing drugs or solutions used.
heb
This significantly complicates the development of inhibitors of different EBOV investigational drugs, some of which have already shown effectiveness in the treatment of Ebola strain (EVD) in nonhuman primates with hits 100% survival, as told them other entries related to the topic.
Such concerns are for future vaccine candidates for the prevention of Ebola. This problem has historically suffered other pandemic vaccines against other infections, such as pandemic influenza (H5N1). It was shown that vaccines developed against the Vietnamese strains were ineffective against H5N1 influenza strains with different genomic sequences or mutations in neighboring regions, such geographical areas as Hong Kong and China.
As reported in the prestigious New England Journal of Medicine on 20 August, the current crisis in West Africa by Ebola may be analogous to the aforementioned.
Thus if we had some difficulty and urgency in finding an effective vaccine, then we will have this other problem, which seems will arrive below and which are already working companies like this, in collaboration with many government agencies, as occurs with vaccine development and the different companies working on its development.
heb
The two drugs that comprise Hemispherx are Alferon® N and Ampligen. First, both drugs have mechanisms of action that are multifaceted, and protect cells from viral pathogenesis. For example, a work of the Japanese National Institute of Health, supported by the University of Alabama, said that both drugs are exceptionally effective against highly virulent viruses, such as SARS. or other highly virulent, providing high cross protection of these types of viruses, much higher than that shown by interferons reactions.
Alferon® N is an FDA approved drug in EE: UU. for the treatment of genital warts caused by human papilloma virus in patients 18 years of age or older. they be therefore necessary data from their clinical trials to establish efficacy in humans against Ebola virus.
Ampligen is an experimental drug. It is a new compound set ribonucleic acid / directed specifically-(RNA) as potential treatment of immune disorders, diseases and / or caused by viruses. The Ebola v irus specifically inhibits the RNA which otherwise could cause an antiviral response would prevent their use. Therefore, Ampligen may be able to overcome this deficiency in the host response. Will also be necessary, as with the above and as with all drugs under development by other companies, the data of the corresponding clinical trials to establish efficacy in humans against Ebola virus.
In summary, considering the little more than sixty million dollars has this company today as market value, taking into account the close last Friday at $ 0.335, considering therefore that is closer to the hell Sky, on success with any of its compounds, can literally be the atomic bomb to the good. But as always, you will be assessing those risks of being purchased in one of these values today, centimeros, capable of the best and the worst.
For my part the graphics are hints in which they frame levels to consider ahead of a potential operational this "bomb" value (for better and for worse, remember).
Good luck with that finger.
Hemispherx Biopharma Hemispherx Biopharma
………………………………………………………………………………………………………………
Quizá también le interese ver: